2023-504376-21-00Active, not recruitingPhase 1
A Phase 1b study to evaluate the safety, pharmacokinetics, and anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in combination with different drugs in patients with advanced solid tumours
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Sept 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 21 Apr 2023
- Start date
- 28 Aug 2023
- Lead sponsor
- Peptomyc S.L.
- Diseases
- Pancreatic cancer
- EU CT number
- 2023-504376-21-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 30
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (6)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Active, not recruiting |
| Institut Catala D'oncologia | L'Hospitalet de Llobregat | Spain | Active, not recruiting |
| Hospital General Universitario Gregorio Marañón | Madrid | Spain | Active, not recruiting |
| Hospital Universitario Regional de Málaga | Málaga | Spain | Active, not recruiting |
| Hospital Universitario Marqués de Valdecilla | Santander | Spain | Active, not recruiting |
| Hospital Unviersitario Miguel Servet | Zaragoza | Spain | Active, not recruiting |
The registry text, word for word
This page is information, not medical advice. Discuss any trial with your doctor.